Summary
Danaher Corporation's 2007 10-K filing reveals a year of significant growth, driven by strategic acquisitions and expansion across its four key segments: Professional Instrumentation, Medical Technologies, Industrial Technologies, and Tools & Components. The company reported a substantial increase in sales, bolstered by the integration of newly acquired businesses, most notably Tektronix, Inc. and ChemTreat, Inc. These acquisitions are expected to contribute to future growth and operational efficiencies. Danaher continues to leverage its Danaher Business System (DBS) to drive performance improvements in quality, delivery, cost, and innovation across its diverse portfolio. Financially, the company demonstrated robust operating cash flow generation. Despite significant investment in acquisitions, Danaher maintained a strong liquidity position. The company also continued its share repurchase program and paid dividends, reflecting a commitment to shareholder returns. Management highlighted ongoing efforts to improve operating profit margins through cost reduction initiatives and strategic sourcing. The company's global reach, with over half of its sales generated outside the U.S., provides diversification and resilience against regional economic fluctuations.
Financial Highlights
34 data points| Revenue | $11.03B |
| Cost of Revenue | $5.99B |
| Gross Profit | $5.04B |
| R&D Expenses | $601.42M |
| SG&A Expenses | $2.71B |
| Operating Expenses | $9.29B |
| Operating Income | $1.74B |
| Interest Expense | $109.70M |
| Net Income | $1.37B |
| EPS (Basic) | $2.20 |
| EPS (Diluted) | $2.10 |
| Shares Outstanding (Basic) | 622.45M |
| Shares Outstanding (Diluted) | 658.92M |
Key Highlights
- 1Danaher achieved significant sales growth in 2007, driven by strategic acquisitions like Tektronix and ChemTreat, complementing its existing businesses.
- 2The company's operational efficiency is managed through the Danaher Business System (DBS), aimed at continuous improvement in quality, delivery, cost, and innovation.
- 3Operating cash flow remained strong, supporting the company's aggressive acquisition strategy and capital allocation priorities.
- 4Danaher continued to invest in research and development across its segments, particularly in Medical Technologies and Professional Instrumentation, to drive future product innovation.
- 5Approximately 51% of Danaher's total sales were generated from international markets, showcasing its global diversification.
- 6The company actively managed its capital structure, utilizing commercial paper and senior notes to finance acquisitions, while also engaging in share repurchases and dividend payments.